395 related articles for article (PubMed ID: 25432773)
21. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
22. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
Binkley N; Bone H; Gilligan JP; Krause DS
Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
[TBL] [Abstract][Full Text] [Related]
24. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
Engelke K; Fuerst T; Dardzinski B; Kornak J; Ather S; Genant HK; de Papp A
J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
[TBL] [Abstract][Full Text] [Related]
25. Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
Binkley N; Krueger D; de Papp AE
Osteoporos Int; 2018 Apr; 29(4):999-1002. PubMed ID: 29455249
[TBL] [Abstract][Full Text] [Related]
26. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
Duong LT; Clark S; Pickarski M; Giezek H; Cohn D; Massaad R; Stoch SA
Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006
[TBL] [Abstract][Full Text] [Related]
27. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
28. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki EM
IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
[TBL] [Abstract][Full Text] [Related]
29. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
30. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
31. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.
Williams DS; McCracken PJ; Purcell M; Pickarski M; Mathers PD; Savitz AT; Szumiloski J; Jayakar RY; Somayajula S; Krause S; Brown K; Winkelmann CT; Scott BB; Cook L; Motzel SL; Hargreaves R; Evelhoch JL; Cabal A; Dardzinski BJ; Hangartner TN; Duong LT
Bone; 2013 Oct; 56(2):489-96. PubMed ID: 23806798
[TBL] [Abstract][Full Text] [Related]
32. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
34. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
[TBL] [Abstract][Full Text] [Related]
35. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
36. Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses.
Gajic-Veljanoski O; Tomlinson G; Srighanthan J; Adachi JD; Josse R; Brown JP; Cheung AM
J Clin Endocrinol Metab; 2014 Sep; 99(9):3070-9. PubMed ID: 24823462
[TBL] [Abstract][Full Text] [Related]
37. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
Stoch SA; Zajic S; Stone J; Miller DL; Van Dyck K; Gutierrez MJ; De Decker M; Liu L; Liu Q; Scott BB; Panebianco D; Jin B; Duong LT; Gottesdiener K; Wagner JA
Clin Pharmacol Ther; 2009 Aug; 86(2):175-82. PubMed ID: 19421185
[TBL] [Abstract][Full Text] [Related]
38. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
39. Treatment of postmenopausal osteoporosis with odanacatib.
Chapurlat RD
Expert Opin Pharmacother; 2014 Mar; 15(4):559-64. PubMed ID: 24456412
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Chen R; Chen C; Geng B; Yang C; Xiao H; Yang F; Wang H; Xia Y
Arch Osteoporos; 2023 May; 18(1):67. PubMed ID: 37169994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]